XML 38 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair value of financial instruments and marketable securities - (Tables)
3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of marketable securities

Ending

Foreign

Ending

Balance at

Currency

Balance at

December 31,

Unrealized

Unrealized

Investments

Redemptions/

March 31,

 

2023

 

Gain

 

Loss

 

Purchased

 

Sale

 

2024

Marketable securities - equity investments

$

22,634

710

(823)

9,065

(1,207)

$

30,379

ClearPoint Equity Investments

6,074

9

6,083

ClearPoint convertible debt security

12,553

166

12,719

Total Fair Value

$

41,261

$

885

$

(823)

$

9,065

$

(1,207)

$

49,181

Ending

Foreign

Ending

Balance at

Currency

Balance at

December 31,

Unrealized

Unrealized

Investments

Redemptions/

March 31,

   

2022

   

Gain/(Loss)

   

Gain

   

Purchased

   

Sale

   

2023

Marketable securities - equity investments

$

108,261

2,166

328

(2,196)

$

108,559

ClearPoint Equity Investments

10,965

(39)

10,926

ClearPoint convertible debt security

15,231

59

15,290

Total Fair Value

$

134,457

$

2,186

$

328

$

$

(2,196)

$

134,775

Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis

March 31, 2024

 

 

Quoted prices

 

Significant

 

 

in active

 

other

 

Significant

 

markets for

 

observable

 

unobservable

 

identical assets

 

inputs

 

inputs

    

Total

    

(level 1)

    

(level 2)

    

(level 3)

Marketable securities - available for sale

$

306,079

$

$

306,079

$

Marketable securities - equity investments

$

30,379

$

30,379

$

$

ClearPoint Equity Investments

$

6,083

$

6,083

$

$

ClearPoint convertible debt security

$

12,719

$

$

12,719

$

Contingent consideration payable- development and regulatory milestones

$

26,900

$

$

$

26,900

Contingent consideration payable- net sales milestones

$

9,300

$

$

$

9,300

December 31, 2023

 

 

Quoted prices

 

Significant

 

 

in active

 

other

 

Significant

 

markets for

 

observable

 

unobservable

 

identical assets

 

inputs

 

inputs

    

Total

    

(level 1)

    

(level 2)

    

(level 3)

Marketable securities - available for sale

$

260,104

$

$

260,104

$

Marketable securities - equity investments

$

22,634

$

22,634

$

$

ClearPoint Equity Investments

$

6,074

$

6,074

$

$

ClearPoint convertible debt security

$

12,553

$

$

12,553

$

Contingent consideration payable- development and regulatory milestones

$

26,600

$

$

$

26,600

Contingent consideration payable- net sales milestones and royalties

$

9,700

$

$

$

9,700

Summary of marketable securities accounted for as available-for-sale debt securities

March 31, 2024

 

Amortized

 

Gross Unrealized

    

Cost

    

Gains

    

Losses

    

Fair Value

Commercial paper

$

132,080

$

26

$

(121)

$

131,985

Government Obligations

174,118

41

(65)

174,094

Total

$

306,198

$

67

$

(186)

$

306,079

December 31, 2023

 

Amortized

 

Gross Unrealized

    

Cost

    

Gains

    

Losses

    

Fair Value

Commercial paper

$

117,044

$

128

$

(12)

$

117,160

Corporate debt securities

 

1,650

(2)

1,648

Government Obligations

141,084

212

141,296

Total

$

259,778

$

340

$

(14)

$

260,104

Summary of unrealized losses and fair values of available-for-sale debt securities in a continuous unrealized loss position

March 31, 2024

 

Securities in an unrealized loss

 

Securities in an unrealized loss

 

 

position less than 12 months

 

position greater than or equal to 12 months

Total

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

Commercial paper

$

(121)

73,250

(121)

73,250

Government bonds

$

(65)

40,302

(65)

$

40,302

Total

$

(186)

$

113,552

$

$

$

(186)

$

113,552

December 31, 2023

 

Securities in an unrealized loss

 

Securities in an unrealized loss

 

 

position less than 12 months

 

position greater than or equal to 12 months

Total

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

Commercial paper

$

(12)

44,446

(12)

44,446

Corporate debt securities

$

(2)

1,648

(2)

$

1,648

Total

$

(12)

$

44,446

$

(2)

$

1,648

$

(14)

$

46,094

Schedule of available-for-sale debt securities

March 31, 2024

 

Less Than

 

More Than

    

12 Months

    

12 Months

Commercial paper

$

131,985

$

Government obligations

174,094

Total

$

306,079

$

December 31, 2023

 

Less Than

 

More Than

    

12 Months

    

12 Months

Commercial paper

$

117,160

$

Corporate debt securities

 

1,648

 

Government obligations

141,296

Total

$

260,104

$

Summary of changes in the fair value of the Company's Level 3 valuation for contingent consideration payable

Level 3 liabilities

Contingent consideration payable-

Contingent consideration payable-

development and regulatory

net sales milestones and royalties

    

milestones

    

Beginning balance as of December 31, 2023

$

26,600

$

9,700

Additions

 

 

Change in fair value

 

300

 

(400)

Payments

Ending balance as of March 31, 2024

$

26,900

$

9,300

Level 3 liabilities

Contingent consideration payable-

Contingent consideration payable-

development and regulatory

net sales milestones and royalties

    

milestones

    

Beginning balance as of December 31, 2022

$

82,500

$

81,500

Additions

 

 

Change in fair value

 

3,000

 

(600)

Payments

Ending balance as of March 31, 2023

$

85,500

$

80,900

Fair value measurement inputs and valuation techniques

March 31, 2024

    

Fair Value

    

Valuation Technique

    

Unobservable Input

    

Range

Contingent consideration payable-
development and regulatory milestones

$26,900

 

 Probability-adjusted discounted cash flow 

 

Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments

$0 - $31 million
85% - 92%
5.9% - 6.2%
2024 - 2026

Contingent considerable payable- net sales
milestones and royalties

$9,300

 

Option-pricing model with Monte Carlo simulation  

 

Potential net sales milestones
Probabilities of success
Potential percentage of net sales for royalties
Discount rate
Projected years of payments

$0 - $50 million
85% - 100%
0%
13.5%
2026 - 2034

December 31, 2023

    

Fair Value

    

Valuation Technique

    

Unobservable Input

    

Range

Contingent consideration payable-
development and regulatory milestones

$26,600

 

 Probability-adjusted discounted cash flow 

 

Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments

$0 - $31 million
85% - 92%
5.8% - 6.1%
2024 - 2026

Contingent considerable payable- net sales
milestones and royalties

$9,700

 

Option-pricing model with Monte Carlo simulation  

 

Potential net sales milestones
Probabilities of success
Potential percentage of net sales for royalties
Discount rate
Projected years of payments

$0 - $50 million
85% - 100%
0%
11%
2026 - 2034